Company news
Pharmaessentia Corp. (TWSE:6446) news
Pharmaessentia Corp. news releases on 6ix. Latest, Sep 9, 2026: PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Press releases & updates
PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
September 9, 2026
FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer
August 31, 2026
Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets
August 24, 2026
PharmaEssentia Announces Health Canada Approval of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
July 7, 2026
PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
July 6, 2026
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen (ropeginterferon alfa-2b-njft) for Polycythemia Vera
June 29, 2026
PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics
June 11, 2026
PharmaEssentia Announces Taiwan Approval of BESREMi® for Essential Thrombocythemia, Marking First Global Approval in ET
June 10, 2026
PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential Thrombocythemia
May 27, 2026
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
May 22, 2026
Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials
April 27, 2026
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health
April 24, 2026
PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico
April 2, 2026
PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®
March 2, 2026
PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
February 9, 2026
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
January 27, 2026
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
January 13, 2026
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
January 12, 2026
PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
December 24, 2025
PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
December 15, 2025
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in the Lancet Haematology
November 25, 2025
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
November 24, 2025
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
November 10, 2025
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
August 18, 2025
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
June 3, 2025
PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
May 20, 2025
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
March 4, 2025
PharmaEssentia Corp. - ICC Arbitral Tribunal rules in favor of AOP Health in arbitration proceedings pertaining to BESREMi
February 18, 2025
CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
January 6, 2025
PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges
January 2, 2025
PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025
December 19, 2024
PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer
December 5, 2024
PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting
November 25, 2024
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
September 4, 2024
PharmaEssentia Appoints Beth A. Krewson as Head of Legal
July 23, 2024
PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE
April 2, 2024
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
November 2, 2023
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate
October 3, 2023
PharmaEssentia Included in FTSE Russell Indices
September 18, 2023
New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera
August 4, 2023
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera
June 30, 2023
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
June 2, 2023
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera
May 23, 2023